[go: up one dir, main page]

AU2003219160A1 - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer

Info

Publication number
AU2003219160A1
AU2003219160A1 AU2003219160A AU2003219160A AU2003219160A1 AU 2003219160 A1 AU2003219160 A1 AU 2003219160A1 AU 2003219160 A AU2003219160 A AU 2003219160A AU 2003219160 A AU2003219160 A AU 2003219160A AU 2003219160 A1 AU2003219160 A1 AU 2003219160A1
Authority
AU
Australia
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219160A
Inventor
Robert Amson
Adam Telerman
Marius Tuijnder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR ENGINES LABORATORIES SA
Original Assignee
MOLECULAR ENGINES LAB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR ENGINES LAB SA filed Critical MOLECULAR ENGINES LAB SA
Publication of AU2003219160A1 publication Critical patent/AU2003219160A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003219160A 2003-03-12 2003-03-12 Methods and compositions for the treatment of cancer Abandoned AU2003219160A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/050059 WO2004080445A1 (en) 2003-03-12 2003-03-12 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2003219160A1 true AU2003219160A1 (en) 2004-09-30

Family

ID=32981714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219160A Abandoned AU2003219160A1 (en) 2003-03-12 2003-03-12 Methods and compositions for the treatment of cancer

Country Status (3)

Country Link
EP (1) EP1656124A1 (en)
AU (1) AU2003219160A1 (en)
WO (1) WO2004080445A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534588T3 (en) * 2007-04-13 2015-04-24 Southern Research Institute Terfenadine as an antiangiogenic agent
ES2710109T3 (en) * 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Nucleic acids that target TCTP for use in the treatment of chemoresistant or hormone-resistant cancers
WO2014098932A1 (en) * 2012-12-17 2014-06-26 The Brigham And Women's Hosptial, Inc. Treatment of mtor hyperactive related diseases and disorders
WO2014137978A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
BR112017015013A2 (en) 2015-01-19 2018-01-23 Belina Pharma Ab antihistamine for use in breast cancer treatment
WO2017000084A1 (en) * 2015-06-30 2017-01-05 上海交通大学 Applications of promethazine in preparation of products for resisting against liver cancer and/or colon cancer and/or lung cancer
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and calamizole compounds to treat inflammatory and cancerous conditions
CN106361752A (en) * 2016-08-31 2017-02-01 清华大学深圳研究生院 New application of flupentixol
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
FR3071726B1 (en) 2017-09-29 2020-09-04 Univ Paris Sud TCTP PROTEIN INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
WO2019204154A1 (en) * 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
CN114432446B (en) * 2020-11-05 2023-07-04 南湖实验室 Application of antihistamine in preparation of antitumor drugs
CN117338780A (en) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 Application of paroxetine in preparation of antitumor drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2426473A1 (en) * 1978-05-26 1979-12-21 Carraz Gilbert Treatment of leukaemia by UV irradiation of blood - in presence of a phenothiazine amine as radiation sensitiser
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
WO1996022085A1 (en) * 1995-01-17 1996-07-25 Pfizer Inc. The use of sertraline to treat cancer patients
US20020019010A1 (en) * 2000-07-07 2002-02-14 Stockwell Brent R. Methods for identifying combinations of entities as therapeutics
FR2825279B1 (en) * 2001-06-01 2005-04-08 Molecular Engines Lab USEFUL MEDICINE IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
WO2004080445A1 (en) 2004-09-23
EP1656124A1 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
EP2671581B8 (en) Compositions and methods for treating cancer
AU2003230750A1 (en) Compositions and methods for treating cancer
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
WO2003073826A8 (en) Novel compositions and methods for cancer
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003298708A1 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase